Bavituximab
Phase 3Monoclonal antibody
Bavituximab was being developed to treat cancer by blocking a protein that helps tumors hide from the immune system, potentially allowing the body's immune cells to better fight the cancer.[1] Bavituximab is currently being investigated across 17 indications[3], with its most advanced program in Phase 3.[1]
Bavituximab is one of 485 small molecule programs targeting Prostate Adenocarcinoma. It is currently in Phase 3.
17
Indications
22
Total Trials
1
Active Trials
484
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 17 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Bavituximab
PPeregrine Pharmaceuticals
Phase 3
Halaven
EisaiPreclinical
Adenocard
AstellasPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Zinecard
CChildren's Oncology Group
Preclinical
Chirocaine
PPurdue Pharma LP
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Paracetamol
GSKPreclinical
Apatinib Mesylate
BBukwang Pharmaceutical
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer5 trials
Hepatocellular Carcinoma3 trials
Lung Cancer3 trials
Chronic Hepatitis2 trials
8 more indications
Chronic Hepatitis C Virus Infection1 trial
Non-Small Cell Lung Cancer1 trial
Solid Tumor Malignancies1 trial
Pembrolizumab1 trial
Rectal Adenocarcinoma1 trial
Pancreatic Cancer1 trial
Treatment1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bavituximab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company
- PPeregrine Pharmaceuticals